Outlook Therapeutics (OTLK) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $10.50 from $10.00 | Sep 11, 2026 |
| BTIG | Maintained | Buy | $4.00 | Aug 14, 2026 |
| BTIG | Upgraded | Neutral → Buy | $4.00 | Jul 27, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $1.60 from $0.50 | Jul 27, 2026 |
| Ascendiant Capital | Maintained | Buy | $10.00 from $6.00 | Jun 11, 2026 |
| BTIG | Downgraded | Buy → Neutral | — | May 18, 2026 |
| Ascendiant Capital | Maintained | Buy | $6.00 from $10.00 | Mar 11, 2026 |
| Chardan Capital | Maintained | Neutral | $1.00 | Feb 18, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $0.50 | Feb 18, 2026 |
| Chardan Capital | Maintained | Neutral | $1.00 from $3.00 | Jan 5, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $0.50 from $1.00 | Jan 2, 2026 |
| Ascendiant Capital | Maintained | Buy | $10.00 from $8.00 | Dec 22, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $1.00 | Sep 30, 2025 |
| Ascendiant Capital | Maintained | Buy | $8.00 from $21.00 | Sep 22, 2025 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | $1.00 | Aug 29, 2025 |
| Guggenheim | Downgraded | Buy → Neutral | — | Aug 29, 2025 |
| Chardan Capital | Maintained | Neutral | $3.00 | Aug 28, 2025 |
| Chardan Capital | Maintained | Neutral | $3.00 | Aug 15, 2025 |
| Ascendiant Capital | Maintained | Buy | $21.00 from $24.00 | Jun 6, 2025 |
| Ascendiant Capital | Maintained | Buy | $24.00 from $33.00 | Feb 24, 2025 |
Frequently asked questions
What is the price target for OTLK stock?
The average 12-month analyst price target for Outlook Therapeutics (OTLK) is $5.37, with a high estimate of $10.50 and a low of $1.60, across 3 analysts.
Is OTLK a buy, sell, or hold?
Analysts covering Outlook Therapeutics currently average a Buy rating: 2 buy, 1 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for OTLK?
The average price target of $5.37 implies 973.33% upside from the last price of $0.50.
What is the latest analyst rating on OTLK?
On Sep 11, 2026, Ascendiant Capital maintained Outlook Therapeutics at Buy with a price target of $10.50.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.